At4g26340 Antibody
Description
Definition and Basic Characteristics
The At4g26340 antibody is a polyclonal or monoclonal antibody generated against the protein product of the At4g26340 gene in Arabidopsis thaliana (mouse-ear cress). This gene is part of the plant's genome, though its specific biological function remains uncharacterized in publicly available literature. The antibody is cataloged with the following identifiers:
-
Product Code: CSB-PA816780XA01DOA
-
UniProt ID: Q8H1R7
-
Host Species: Immunogen-derived from Arabidopsis thaliana
Table 1: Potential Workflows for At4g26340 Antibody
| Application | Purpose | Example Techniques |
|---|---|---|
| Protein Localization | Subcellular tracking of At4g26340 | Fluorescence microscopy |
| Expression Profiling | Quantifying protein levels under stress or developmental conditions | Western blot, ELISA |
| Interaction Studies | Identifying binding partners via co-immunoprecipitation | IP-MS (Immunoprecipitation-Mass Spectrometry) |
Key Knowledge Gaps:
-
No peer-reviewed studies directly utilizing this antibody were identified in the provided sources.
-
The protein’s role in Arabidopsis metabolism, stress response, or growth regulation remains unelucidated.
Recommendations for Researchers
-
Validation: Perform independent validation using knockout Arabidopsis lines to confirm specificity.
-
Epitope Mapping: Use techniques like peptide arrays to identify the exact binding region.
-
Collaborative Studies: Partner with plant genomics consortia to explore At4g26340’s role in plant biology.
Limitations and Cautions
Product Specs
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Q&A
Based on the analysis of current antibody research methodologies and challenges presented in the literature, here is a structured FAQ addressing key aspects of antibody development and validation relevant to academic investigations:
How do researchers validate antibody specificity for experimental use?
-
Methodological approach:
-
Perform immunoprecipitation (IP) followed by mass spectrometry to confirm target protein enrichment and detect off-target binding partners (e.g., 5E4 antibody's cross-reactivity with AMPD2/TRIM28)
-
Use isotype controls and knockout cell lines to establish baseline specificity
-
Conduct dot-blot assays with mutant vs. wild-type antigens (e.g., A4 antibody validation for I223R/H275Y neuraminidase)
-
What experimental designs effectively compare antibody binding affinities?
-
Core strategies:
What strategies improve antibody therapeutic potential while minimizing toxicity?
-
Bispecific engineering:
-
Affinity maturation:
How to address antibody functional divergence between in vitro and in vivo models?
-
Validation pipeline:
Methodological Recommendations
-
For structural studies: Combine X-ray crystallography (2.8Å resolution minimum) with molecular dynamics simulations to validate binding interfaces
-
In functional assays: Implement reporter cell systems (e.g., HEK-Blue IL-4/IL-13) for quantitative pathway inhibition measurements
-
For clinical translation: Conduct parallel human/murine cross-reactivity testing early in development
